invasive aspergillosis

Clinico-immunological features of invasive aspergillosis in patients with Hodgkin’s disease

INFECTIONS IN ONCOHEMATOLOGY , ,

O.V. Shadrivova1, Ye.V. Frolova1, L.V. Filippova1, A.Ye. Uchevatkina1, S.N. Khostelidi1, R.M. Chernopyatova1, Ye.A. Desyatik1, A.G. Volkova2, Ye.V. Shagdileyeva1, L.S. Zubarovskaya2, A.V.Rysev1, S.M. Ignatyeva1, T.S. Bogomolova1, Yu.N. Vinogradova3, N.V. Vasilyeva1, and N.N. Klimko1

1 I.I. Metchnikov Northwest State Medical University, Saint Petersburg, Russian Federation

2 R.M. Gorbacheva Institute of Pediatric Oncology, Hematology and Transplantology, I.P. Pavlov Saint Petersburg State Medical University, Saint Petersburg, Russian Federation

3 Russian Research Centre for Radiology and Surgical Technologies, RF Ministry of Health, Saint Petersburg, Russian Federation

ABSTRACT

Invasive aspergillosis is a serious mycotic infection with high mortality that mostly occurs in patients with hematological malignancies and severe immunodeficiency. Immunological defects in the various groups of hematological patients with invasive aspergillosis are not well understood. We are the first to present the results of studying clinico-immunological features of invasive aspergillosis in the patients with Hodgkin’s lymphoma.

Keywords: invasive aspergillosis, Hodgkin’s lymphoma, immune response.

Read in PDF (RUS) pdficon

REFERERENCES

  1. Kousha M., Tadi R., Soubani A.O. Pulmonary aspergillosis: a clinical review. Eur. Respir. Rev. 2011; 20(21): 156–72.
  2. Попова М.О., Зубаровская Л.С., Климко Н.Н., Афанасьев Б.В. Инва- зивные микозы при трансплантации гемопоэтических стволовых клеток. Тер. арх. 2012; 7: 50–7. [Popova M.O., Zubarovskaya L.S., Klimko N.N., Afanasyev B.V. Invasive mycoses in hematopoietic stem cell transplantation. Ter. arkh. 2012; 7: 50–7. (In Russ.)].
  3. Klimko N.N., Shadrivova O.V., Khostelidi S.N. et al. Invasive aspergillosis in Saint Petersburg, Russia: analysis of 445 proven and probable cases. Mycos. Diagn. Ther. Prophyl. Fungal Dis. 2013; 56(3): 113.
  4. Chaudhary N., Staab J.F., Marr K.A. Healthy Human T-Cell Responses to Aspergillus fumigatus Antigens. PLoS One 2010; 5(2): e9036.
  5. Carvalho A., Cunha C., Bistoni F., Romani L. Immunotherapy of aspergillosis. Microbiol. Infect. 2012; 18(2): 120–5.
  6. De Pauw B., Walsh T.J., Donnelly J.P. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 2008; 46(12): 1813–21.
  7. Drgona L., Colita A., Klimko N. et al. Triggers for driving treatment of at-risk patients with invasive fungal disease. J. Antimicrob. Chemother. 2013; 68(3): 17–24.
  8. Landgren O., Pfeiffer R.M., Kristinsson S.Y., Bjorkholm M. Survival patterns in patients with Hodgkin’s Lymphoma with a pre-existing hospital discharge diagnosis of autoimmune disease. J. Clin. Oncol. 2010; 28(34): 5081–7.
  9. Landgren O., Engels E.A., Pfeiffer R.M. et al. Autoimmunity and Susceptibility to Hodgkin Lymphoma: A Population-Based Case–Control Study in Scandinavia. J. Nat. Cancer Inst. 2006; 98(18): 1321–30.
  10. Brusamolino E., Carella A.M. Treatment of refractory and relapsed Hodgkin’s lymphoma: facts and perspectives. Hematol. J. Open Access Publ. 2007; 92(1): 6–10.
  11. Лимфомы: научно-практическое издание. Под ред. А.М. Гранова, Н.В. Ильина. СПб., 2010: 272. [Limfomy: nauchno-prakticheskoe izdanie. Pod red. A.M. Granova, N.V. Ilina (Lymphomas: scientific-and-practical publication. Ed. by: A.M. Granov, N.V. Ilin). SPb., 2010: 272 .]
  12. Chai L.Y., Vonk A.G., Kullberg B.-J., Netea M.G. Immune Response to Aspergillus fumigatus in Compromised Hosts: From Bedside to Bench. Fut. Microbiol. 2011; 6(1): 73–83.
  13. Zitvogel L., Apetoh L., Ghiringhelli F., Kroemer G. Immunological aspects of cancer chemotherapy. Immunology 2008; 8: 59–73.
  14. Motoyoshi Y., Kaminoda K., Saitoh O. et al. Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol. Rep. 2006; 16(1): 141–6.
  15. Segal B.H. Role of macrophages in host defense against aspergillosis and strategies for immune augmentation. Oncologist 2007; 12(2): 7–13.
  16. Stevens D.A. Th1/Th2 in aspergillosis. Med. Mycol. 2006; 44(1): 229–35.
  17. Chai L.Y., Netea M.G., Teerenstra S. et al. Early Proinflammatory Cytokines and C-Reactive Protein Trends as Predictors of Outcome in Invasive Aspergillosis. J. Infect. Dis. 2010; 202(9): 1454–62.
  18. Фролова Е.В., Шадривова О.В., Филиппова Л.В. и др. Состояние иммунного статуса у гематологических пациентов с инвазивным аспергил- лезом. Журн. инфектол. 2012; 4(4): 59–64. [Frolova Ye.V., Shadrivova O.V., Filippova L.V., et al. Immune status in hematological patients with invasive aspergillosis. Zhurn. infektol. 2012; 4(4): 59–64. (In Russ.)].
  19. Park S.J., Mehrad B. Innate Immunity to Aspergillus Species. Clin. Microbiol. Rev. 2009; 22(4): 535–51.
  20. Hebart H., Bollinger C., Fisch P. et al. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. Blood 2002; 100(13): 4521–8.
  21. Chai L.Y., van de Veerdonk F., Marijnissen R.J. et al. Anti-Aspergillus human host defense relies on type 1 T helper (Th1), rather than type 17 T helper (Th17), cellular immunity. Immunology 2010; 130(1): 646–54.
  22. Van de Veerdonk F., Netea M.G. T-cell Subsets and Antifungal Host Defenses. Curr. Fung. Infect. Rep. 2010; 4(4): 238–43.